Financial Personal
Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting
– Interim 24-week data from the NEUROFUSE study highlights the safety and efficacy of NTX-001 for peripheral nerve injuries. CHESTERBROOK, Pa. — Neuraptive Therapeutics Inc., a leading biopharmaceutical company focused on novel treatments